Optimization of triarylimidazoles for Tie2: Influence of conformation on potency

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 20, 2007, Pages 5514-5517

  Johnson, Neil W ^a   Semones, Marcus ^a   Adams, Jerry L ^a   Hansbury, Michael ^b   Winkler, Jim ^c  

^a GLAXOSMITHKLINE   (United States)

^b Incyte Pharm ^*  (United States)

^c ARRAY BIOPHARMA INC   (United States)

Author keywords

Angiogenesis; Cancer; Tie2 kinase

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; IMIDAZOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONFORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN;

IMIDAZOLES; INHIBITORY CONCENTRATION 50; METHYLATION; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN KINASE INHIBITORS; RECEPTOR, TIE-2; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 34548555594     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.052     Document Type: Article

References (14)

1. Jones N., Iljin K., Dumont D.J., and Alitalo K. Nat. Rev. Mol. Cell Biol. 2 (2001) 257
2. Tsigkos S., Koutsilieris M., and Papapetropoulos A. Expert Opin. Investig. Drugs 12 (2003) 935
3. Lin P., Buxton J., Acheson A., Radziejewski C., Maisonpierre P., Yancopoulos G., Channon K., Hale L., Dewhirst M., George E., and Peters K. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8829
4. Siemeister G., Schirner M., Weindel K., Reusch P., Menrad A., Marme D., and Martiny-Baron G. Cancer Res. 59 (1999) 3185
5. Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., and Ying Q. Nature 376 (1995) 70
6. Ferrara N., Hillan K.J., Gerber H.-P., and Novotny W. Nat. Rev. Drug Disc. 3 (2004) 391
7. Semones, M.; Feng, Y.; Johnson, N. W.; L. Adams, J. L.; Winkler J.; Hansbury, M. Biorg. Med. Chem. Lett. 2007, 17, 4756.
8. Crystallographic data (excluding structure factors) for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 646583 and 646584. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].
9. The homology model of Tie2 was generated in the program MOE using the crystal structure FGFR-2 kinase (PDB code 1oec) as the structural template; compounds 1-3 were manually docked into the homology model based on the bound conformation of SB-203850 in crystal structure 1a9u. Figure 2 depicts the manual docking model for compound 1 in a second-generation homology model of an active form of Tie2; this second-generation homology model was generated in the program MOE using the crystal structures of inactive Tie2 (PDB code 1fvr) and active FGFR-2 kinase (PDB code 1oec) as structural templates. Figures were generated using the program pymol.
10. Volkamer K., and Zimmerman H. Chem. Ber. 102 (1969) 4177
11. Liverton N.J., Butcher J.W., Claiborne C.F., Claremon D.A., Libbey B.E., Nguyen K.T., Pitzenberger S.M., Selnick H.G., Smith G.R., Tebben A., Vacca J.P., Varga S.L., Agarwal L., Dancheck K., Forsyth A.J., Fletcher D.S., Frantz B., Hanlon W.A., Harper C.F., Hofsess S.J., Kostura M., Lin J., Luell S., O'Neill E.A., Orevillo C.J., Pang M., Parsons J., Rolando A., Sahly Y., Visco D.M., and O'Keefe S.J. J. Med. Chem. 42 (1999) 2180
12. Calculated dihedral angles for compound 23 using MOE are; C-2 aryl to imidazole 65°, pyridine to imidazole 38°, naphthyl to imidazole 66°.
13. Biancone L., De Martino A., Orlandi V., Conaldi P.G., Toniolo A., and Camussi G. J. Exp. Med. 186 (1997) 147
14. Drabkin D.L., and Austin J.H. J. Biol. Chem. 112 (1935) 51